恒瑞医药(01276)子公司获国家药监局核准签发关于SHR-1894 注射液的《药物临床试验批准通知书》

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of SHR-1894 injection, a self-developed biological product aimed at treating atopic dermatitis [1] Group 1: Product Development - SHR-1894 injection is expected to protect the skin barrier and suppress inflammation during the treatment of atopic dermatitis [1] - There are currently no similar drugs approved for market in both domestic and international markets [1] - The total research and development investment for SHR-1894 injection has reached approximately 40.1 million yuan (unaudited) [1]